In FIGHT-202, all patients with reductions in tumor size followed by PD (n = 8) had developed one or more mutation in the kinase domain of FGFR2 predicted to promote kinase activation or impair pemigatinib binding.6 Here, FGFR2 is linked to neoplasm.